ERBB2 and neoplasm: The combined detection of claudin18.2 and other targeted therapeutic targets, such as HER-2, PD-L1, MMR, and tumour-infiltrating lymphocytes (TILs), will facilitate the exploration of combined multitarget treatment strategies and the prediction of the response to these therapies for patients with POMCs and MGMCs.